You are about to leave the Clinical Value website now.

Cancel

Efficacy analysis of combined detection of 5 serological tumor markers including MIF and PIVKA-II for early diagnosis of primary hepatic cancer

Quick Summary

The aim of this study was to investigate the efficacy of combined detection of 5 serological tumor markers including macrophage migration inhibitory factor (MIF) and abnormal prothrombin (PIVKA-II) in the early diagnosis of primary liver cancer.

 

A total of 90 patients with suspected primary liver cancer admitted from January 2016 to May 2017 were selected as the research subjects. All patients were examined by imaging and histopathology. Enzyme-linked immunosorbent assay (ELISA) was used to detect serum MIF, GP73 and PIVKA-II. Automatic electrochemiluminescence immunoassay system was used to detect serum AFP and AFP-L3. The diagnostic value of single and combined detection of five serological tumor markers for primary liver cancer was compared and analyzed.

You May Also Like

SHARE

Be the first to receive updates, event opportunities, and thought leadership insights.